McClarren Financial Advisors’s AbbVie ABBV Stock Holding History

McClarren Financial Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-731	Closed	-$161K	–	75
2025 Q1	$161K	Sell	731 -39	-5%	-$7.58K	0.11%	79
2024 Q4	$137K	Buy	770 +63	+9%	+$11.6K	0.38%	44
2024 Q3	$71	Buy	707 +364	+106%	+$67.9K	0.01%	108
2024 Q2	$114K	Sell	343 -327	-49%	-$54.2K	0.08%	102
2024 Q1	$122K	Buy	670 +1	+0.1%	+$172	0.09%	98
2023 Q4	$104K	Buy	669 +4	+0.6%	+$583	0.08%	104
2023 Q3	$99K	Buy	665 +3	+0.5%	+$440	0.09%	100
2023 Q2	$89K	Buy	662 +3	+0.5%	+$440	0.07%	113
2023 Q1	$104K	Buy	659 +2	+0.3%	+$306	0.09%	98
2022 Q4	$106K	Hold	657	–	–	0.1%	98
2022 Q3	$88K	Buy	+657	New	+$94.3K	0.09%	96
2022 Q2	–	Sell	-357	Closed	-$57K	–	34
2022 Q1	$57K	Hold	357	–	–	0.04%	116
2021 Q4	$49K	Hold	357	–	–	0.03%	140
2021 Q3	$38K	Hold	357	–	–	0.03%	133
2021 Q2	$40K	Hold	357	–	–	0.03%	133
2021 Q1	$39K	Hold	357	–	–	0.03%	124
2020 Q4	$38K	Buy	+357	New	+$34.3K	0.04%	114

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

McClarren Financial Advisors's ABBV Position: Q2 2025 in Review

McClarren Financial Advisors sold out of AbbVie (ABBV) in Q2 2025, closing a stake of 731 shares — an estimated $161K sold.

McClarren Financial Advisors first reported a position in ABBV in Q4 2020 and held it in 17 quarters. The position peaked at $161K in Q1 2025. 3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

McClarren Financial Advisors reported no remaining AbbVie position as of Q2 2025 after selling out during the quarter.
McClarren Financial Advisors sold 731 AbbVie shares in Q2 2025, an estimated $161K.
McClarren Financial Advisors first reported a position in AbbVie in Q4 2020 and held it in 17 quarters.
McClarren Financial Advisors's AbbVie position peaked at $161K in Q1 2025.
3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on McClarren Financial Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.